All In Biotech

Drug Trial Radar · NCT05221021

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

Vaginal Estradiol vs Oral Beta-3 Agonist for Treatment of Overactive Bladder Syndrome: A Single-Therapy, Double-Blind, Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Aug 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

152

Planned (sponsor's estimate)

Start

Oct 1, 2022

Primary completion

Dec 30, 2026

Study completion Jan 30, 2027

Sponsor

Sponsor type
Federal agency
First posted
Feb 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A single site, double-blinded, randomized controlled trial for postmenopausal women with urinary frequency, urgency, nocturia with or without urgency urinary incontinence symptoms. Patient's will be randomized between 0.01% vaginal estradiol cream with placebo oral pill or daily 50 milligrams oral Mirabegron with a placebo vaginal cream for 12 weeks.

Conditions

  • Overactive Bladder Syndrome

Interventions

  • Vaginal estrogenDrug

    0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill

  • Mirabegron 50 MG [Myrbetriq]Drug

    50mg oral Mirabegron once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. OAB-q short form (SF) symptom bother scoresTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Walter Reed National Military Medical Center

    Bethesda, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.